Biological Activity
PTACH (NCH-51) is a SAHA-based novel inhibitor of human HDAC. PTACH exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1 to 10 μM.
In Vitro
In cancer cell growth inhibition assay, PTACH shows strong activity. PTACH inhibits various cancer cells with EC50 of 2.3, 9.1, 3.0, 2.6, 1.1, 4.5, 2.4, 5.0, and 4.5 μM for MDA-MB-231 breast cancer, SNB-78 central nervous system, HCT116 colon cancer, NCI-H226 lung cancer, LOX-IMVI melanoma, SK-OV-3 ovarian cancer, RXF-631L renal cancer, St-4 stomach cancer, and DU-145 prostate cancer.
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Target
IC50 value: 1-10 μM (EC50) Target: HDAC
References & source
[1]. Suzuki T, et al. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-1032.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
